Enanta Pharmaceuticals Price Target Increased to $50.00 by Analysts at JMP Securities (ENTA)
Investment analysts at JMP Securities hoisted their price objective on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) to $50.00 in a note issued to investors on Tuesday, American Banking News.com reports. The firm currently has an “outperform” rating on the stock. JMP Securities’ price target would indicate a potential upside of 29.60% from the stock’s previous close.
Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) opened at 38.58 on Tuesday. Enanta Pharmaceuticals has a 52 week low of $14.31 and a 52 week high of $40.45. The stock’s 50-day moving average is $33.11 and its 200-day moving average is $24.91. The company’s market cap is $692.4 million.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Thursday, February 13th. The company reported ($0.30) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.15) by $0.15. The company had revenue of $0.89 million for the quarter, compared to the consensus estimate of $1.41 million. On average, analysts predict that Enanta Pharmaceuticals will post $1.39 earnings per share for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Credit Suisse raised their price target on shares of Enanta Pharmaceuticals from $36.00 to $43.00 in a research note on Monday, February 10th. Separately, analysts at Robert W. Baird initiated coverage on shares of Enanta Pharmaceuticals in a research note on Monday, January 27th. They set an “outperform” rating and a $41.00 price target on the stock. Finally, analysts at Zacks downgraded shares of Enanta Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Wednesday, January 1st. They now have a $33.30 price target on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Enanta Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $41.83.
In other Enanta Pharmaceuticals news, CEO Jay Luly unloaded 5,800 shares of Enanta Pharmaceuticals stock on the open market in a transaction dated Friday, February 14th. The shares were sold at an average price of $38.10, for a total transaction of $220,980.00. Following the completion of the transaction, the chief executive officer now directly owns 569,338 shares of the company’s stock, valued at approximately $21,691,778. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.